Drug Drug Interactions of Aspirin and P2Y12-inhibitors

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Study Objective: To investigate potential drug-drug interactions (pharmacokinetics and pharmacodynamics) of morphine and antiplatelet drugs (aspirin, clopidogrel, prasugrel, ticagrelor)

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Medical University of Vienna
• Treatments: Morphine

Criteria

Inclusion Criteria:

• Healthy volunteers ≥ 18 years of age

• No intake of NSARs and P2Y12-inhibitors within 14 days before study entry

• Written informed consent

Exclusion Criteria:

• Known coagulation disorders

• Relevant impairment of hepatic function (elevated transaminases, ≥ 2 fold)

• Relevant impairment of renal function

• Infectious diseases (HIV, hepatitis B and C)

• Gestation and lactation

• Clinically relevant abnormal laboratory values

• Use of medication during 2 weeks before the start of the study, which may affect the validity of the study

• General contraindications for aspirin (resp. clopidogrel, prasugrel, ticagrelor) and morphine